iCAD Reports Financial Results For Second Quarter 2022
August 10, 2022 16:07 ET
|
iCAD, Inc.
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second...
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
July 27, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
July 13, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., July 13, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the...
ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series
June 29, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., June 29, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that...
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk
June 07, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., June 07, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its next...
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
June 06, 2022 08:08 ET
|
iCAD, Inc.
NASHUA, N.H., June 06, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company...
iCAD Announces CFO Transition
May 25, 2022 08:01 ET
|
iCAD, Inc.
NASHUA, N.H., May 25, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of...
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
May 18, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., May 18, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new...
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
May 16, 2022 08:00 ET
|
iCAD, Inc.
NASHUA, N.H., May 16, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that...
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
May 11, 2022 16:07 ET
|
iCAD, Inc.
NASHUA, N.H., May 11, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial...